Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,298 INR | -1.28% | -2.97% | +16.56% |
29/03 | Ipca Laboratories Limited Announces Cessation of Anand T. Kusre as an Independent Director | CI |
29/03 | Ipca Laboratories Limited Appoints Swati Arvind Patankar as an Independent Director | CI |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 63% by 2026.
- The company's profit outlook over the next few years is a strong asset.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Analyst opinion has improved significantly over the past four months.
Weaknesses
- With an expected P/E ratio at 53.25 and 34.89 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company's enterprise value to sales, at 4.54 times its current sales, is high.
- The company appears highly valued given the size of its balance sheet.
- The company is not the most generous with respect to shareholders' compensation.
- For the last few months, analysts have been revising downwards their earnings forecast.
- The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+16.56% | 398.75Cr | C+ | ||
+30.38% | 68TCr | C+ | ||
+29.48% | 57TCr | B | ||
-4.36% | 36TCr | C+ | ||
+19.30% | 33TCr | B- | ||
+3.73% | 28TCr | C+ | ||
+16.42% | 24TCr | B+ | ||
+9.63% | 21TCr | B- | ||
-7.24% | 20TCr | A+ | ||
+7.68% | 17TCr | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- IPCALAB Stock
- IPCALAB Stock
- Ratings Ipca Laboratories Limited